Business · 27/09/2018Updated: 10/17/2026 · 1 min read
FDA Announces Fee Rate for Rare Pediatric Disease Priority Review Voucher for Fiscal Year 2019
Summary
The US Food and Drug Administration (FDA) has set the fee rate for using a rare pediatric disease priority review voucher for fiscal year 2019, based on the average cost of reviewing human drug applications designated as priority review in the previous year.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →